Advancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosis Montiel Troya, María Mohamed Mohamed, Himan Pardo Moreno, Teresa González Díaz, Ana Rúger Navarrete, Azahara de la Mata Fernández, Mario Tovar Gálvez, María Isabel Ramos Rodríguez, Juan José García-Morales, Victoria ALS Amyotrophic lateral sclerosis Neurodegenerative disorder (1) Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which the patient suffers from an affection of both upper and lower motor neurons at the spinal and brainstem level, causing a progressive paralysis that leads to the patient’s demise. Gender is also considered a predisposing risk factor for developing the disease. A brief review of the pathophysiological mechanisms of the disease is also described in this work. Despite the fact that a cure for ALS is currently unknown, there exists a variety of pharmacological and non-pharmacological therapies that can help reduce the progression of the disease over a certain period of time and alleviate symptoms. (2)We aim to analyze these pharmacological and non-pharmacological therapies through a systematic review. A comprehensive, multidisciplinary approach to treatment is necessary. (3) Drugs such as riluzole, edaravone, and sodium phenylbutyrate, among others, have been investigated. Additionally, it is important to stay updated on research on new drugs, such as masitinib, from which very good results have been obtained. (4) Therapies aimed at psychological support, speech and language, and physical therapy for the patient are also available, which increase the quality of life of the patients. 2024-11-07T12:02:11Z 2024-11-07T12:02:11Z 2024-09-27 journal article Montiel-Troya,M.; Mohamed-Mohamed, H.; Pardo-Moreno, T.; González-Díaz, A.; Ruger-Navarrete, A.; de laMata Fernández,M.; Tovar-Gálvez,M.I.; Ramos-Rodríguez, J.J.; García-Morales, V. Advancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosis. Biomedicines 2024, 12, 2200. https://doi.org/10.3390/biomedicines12102200 https://hdl.handle.net/10481/96740 10.3390/biomedicines12102200 eng http://creativecommons.org/licenses/by/4.0/ open access Atribución 4.0 Internacional MDPI